Optruma (Raloxifene Hydrochloride)

Raloxifene Hydrochloride, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as a tablet for oral use. It is prescribed to improve bone density in postmenopausal women and to lower the risk of invasive breast cancer in eligible patients.

GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory compliance across diverse markets.

Raloxifene is a selective estrogen receptor modulator that acts on bone and breast tissue pathways.

Postmenopausal osteoporosis: increases bone mineral density and reduces vertebral and non‑vertebral fracture risk. Osteopenia in postmenopausal women: helps maintain bone mass and prevent progression to osteoporosis. Breast cancer risk reduction: lowers incidence of invasive estrogen‑receptor‑positive breast cancer in high‑risk postmenopausal women.

Raloxifene may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient feeling of warmth, often with sweating. - Leg cramps: muscle discomfort, especially in calves. - Nausea: mild stomach upset. - Headache: occasional tension‑type pain.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs, requiring immediate medical attention. - Stroke: rare cerebrovascular event, especially in patients with vascular risk factors. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing raloxifene, several safety considerations should be observed.

Assess bone health: perform baseline bone mineral density testing before initiation. Screen for thromboembolic history: avoid use in patients with prior DVT or PE. Monitor lipid profile: raloxifene may increase triglycerides. Evaluate liver function: adjust use in moderate hepatic impairment. Consider menopausal status: indicated primarily for postmenopausal women. Store at ambient temperature: keep in original container, protect from moisture and light.

Raloxifene can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: may diminish raloxifene’s bone‑protective effect. - Warfarin: increased anticoagulant effect, raising bleeding risk. - Tamoxifen: antagonistic action on breast tissue may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations of raloxifene. - CYP3A4 inducers (e.g., rifampin): may lower drug levels, reducing effectiveness. - SSRIs (e.g., fluoxetine): may exacerbate hot‑flash symptoms.